Mycophenolate Mofetil for Autoimmune Hepatitis A Single Practice Experience
-
PubMed
(0) (0 Votes)Views: (1021) Date: (29-12-08) Pages: () -
Author: Wolf DC Bojito L Facciuto M Lebovics E.
-
Abstract: Division of Gastroenterology and Hepatobiliary Diseases, New York Medical College, Munger Pavilion Room 206, Valhalla, NY, 10595, USA, david_wolf@nymc.edu.
Related Documents
Related Groups
Related Science News
More on Sciencestage
Answers
- Resolved Question: What salt content is in Cellcept (mycophenolate mofetil)?
Does Cellcept (mycophenolate mofetil) affect blood presure? - Resolved Question: Role of Enteric coated mycophenolate sodium tablets?
In case of nephrotic syndrome - Open Question: why is MMF(Mycophenolate mofetil 500-mg) taken?
- Undecided Question: can you get high off mycophenolate?
just wondering - Resolved Question: Cyclophosphamide & Mycophenolate?
I am currently waiting for results from a kidney biopsy and have been told the above 2... - Undecided Question: Cellcept (mycophenolate mofetil) side effect?
Hi, I had a liver transplant 12 years ago due to PSC and been on Tacrolimus (prograf) since. no problem... - Resolved Question: Do cancer Patients take the medicine called ?
Tacrolimus Valgancyclovir Mycophenolate Prednisone because some of these meds say... - Resolved Question: How serious is Focal Segmental Glomerulo Sclerosis? Anyone has any suggestions to improve treatment …
...to 15mg A/D. 29-Oct-03Fifth relapse. Put on Mycophenolate Mofetil (Tab.Mycept) 250mg 1-0-1 + Prednisolone... - Undecided Question: Pregnancy while husband is on cellcept drug?
...husband has taken cellcept (mycophenolate mofetil) for a medical study and his last dose... - Resolved Question: What does "Mylan 472" mean?
...what is supposed to be Mycophenolate 500MG, or CellCept. They belong to my dad, who...
News
- Research and Markets: Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Research and Markets has announced the addition of GlobalData's new report "Myasthenia Gravis Therapeutics - P - Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
NEW YORK, Feb. 8, 2012 Â /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts ... - EMA CHMP issues positive opinion to MSD's REMICADE for treatment of pediatric UC
MSD today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the use of REMICADE (infliximab) in the treatment of severely active ulcerative colitis (UC) in pediatric patients ages 6 to 17 years, who have had an inadequate response to conventional therapy, including corticosteroids and 6 ... - Merck Serono enters development agreement with Threshold for hypoxia-targeted drug
Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that a global agreement was signed with Threshold Pharmaceuticals, Inc., South San Francisco, to co-develop and commercialize TH-302, Threshold's small molecule hypoxia-targeted drug. - FDA Permits Marketing of First Test For Risk of Rare Brain Infection in Some People Treated With Tysabri
SILVER SPRING, Md., Jan. 20, 2012 /PRNewswire-USNewswire/ -- Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn's disease (CD). - A genetic accelerator hits the gas on autoimmune diseases
( Catholic University of Rome ) A "genetic accelerator" is responsible for the most severe cases of lupus (systemic lupus erythemathosus), an autoimmune disease: the accelerator, called enhancer HS1.2, speeds up the activity of some critical genes of the immune system involved in the disease. - New Tysabri PML Risk Factor Identified
The Food and Drug Administration has identified a new risk factor which could lead to the life-threatening brain infection known as progressive multifocal leukoencephalopathy (PML) associated with the use of the drug Tysabri. Tysabri is prescribed as a “last resort” … Continue reading → - Skin, lung disorder gets more attention
A center at the U is testing the effectiveness of two experimental drugs in the treatment of a skin disorder, scleroderma. The study, sponsored by the National Institutes of Health, seeks to build on last year’s research to improve lung function in patients affected by the disorder that affects the skin, blood vessels and internal [...] - Researchers discover HS1.2 enhancer as the cause of SLE
A "genetic accelerator" is responsible for the most severe cases of Lupus (systemic lupus erythemathosus), an autoimmune disease: the accelerator, called enhancer HS1.2, speeds up the activity of some critical genes of the immune system involved in the disease.
Related on Wikipedia